Medical disclaimer: This website is for research and education only. Nothing here is medical advice, diagnosis, treatment, or a recommendation to use any peptide, supplement, or protocol. Always consult a qualified healthcare provider before making health decisions. Read the full disclaimer.
Recent publications discuss SS-31, but the supplied literature does not establish new efficacy or safety conclusions. This update separates direct reviews from broader translational context.
SS-31, also called elamipretide, appears directly in two supplied 2026 publications. One article described mechanistic foundations, clinical evidence, and potential applications across mitochondrial and other contexts, while the other was presented as a systematic review and meta-analysis of fatigue-related outcomes in mitochondrial-disease trials. Both appeared in International Blest Scientific in 2026 (doi:10.65671/g269y606 and doi:10.65671/ft79c689).
However, the supplied citation records do not include study populations, trial phases, endpoint definitions, effect estimates, adverse-event tables, risk-of-bias assessments, or meta-analytic statistics. It is therefore not possible to verify from these records whether the publications identified a clinically meaningful benefit, a null result, or important safety signals. Their 2026 citation counts were also zero at the time represented in the supplied dataset; that reflects limited citation history, not proof for or against scientific quality.
The fatigue-focused review framed trials in mitochondrial diseases as potentially relevant to chronic fatigue syndrome and related disorders, according to its title in International Blest Scientific (2026). That is a translational hypothesis rather than evidence that results from genetically or clinically defined mitochondrial diseases apply to a different fatigue-related condition. Differences in disease biology, enrollment criteria, outcome measures, background care, and follow-up can prevent direct generalization.
Mitochondrial research can involve multiple outcomes, such as symptoms, physical performance, biomarkers, and patient-reported function. Kokkali and Karalis proposed a vector-based framework for comparing multi-endpoint trials in Clinical and Translational Discovery (2026; doi:10.1002/ctd2.70180). That paper was not identified as an SS-31 trial, but its methodological focus illustrates why an isolated change in one endpoint should not automatically be treated as evidence of broad clinical benefit.
Interpretation should establish whether endpoints were prespecified, whether multiple comparisons were controlled, how missing observations were handled, and whether statistical changes were clinically meaningful. The supplied SS-31 citations do not provide those details. The unrelated stannous-fluoride trials in JDR Clinical & Translational Research (2024; doi:10.1177/23800844241263031) do not contribute evidence about SS-31 merely because they were randomized controlled trials.
Tohkin, Saito, Uyama and colleagues examined Asian cooperation in multi-regional clinical trials from a Japanese regulatory perspective in Clinical and Translational Science (2025; doi:10.1111/cts.70347). This was not direct evidence about elamipretide. It nevertheless highlights a relevant development issue: multinational programs must evaluate whether regional differences in participants, medical practice, and regulation affect interpretation.
Smith discussed safety planning for paused clinical trials in Clinical and Translational Science (2025; doi:10.1111/cts.70465), while Benzian considered pressures affecting clinical and translational research in JDR Clinical & Translational Research (2026; doi:10.1177/23800844261466249). These publications concern research conduct rather than SS-31 efficacy. They reinforce that continuity of follow-up, participant protection, transparent reporting, and operational stability are part of the evidentiary picture.
The supplied 2026 literature shows continued interest in elamipretide and in fatigue-related outcomes, but it does not provide enough primary data to support a new conclusion about efficacy, safety, dosing, or use in any specific condition. The most directly relevant items are secondary publications, and the other papers address trial methodology, regulation, research pressure, or unrelated interventions.
A stronger update would require full trial reports with prespecified endpoints, participant characteristics, comparator details, effect sizes with uncertainty intervals, adverse-event data, attrition, follow-up duration, and risk-of-bias assessment. This guide is research information only. It is not medical advice, does not recommend SS-31 or any dose, and should not be used to guide treatment or self-experimentation.
Research and educational information only — not medical advice.